argenx
Heleen Dewitte is a Senior Scientist in Discovery at argenx since December 2020, previously serving as a Scientist in the same department. Prior experience includes a Post-doctoral fellowship at Ghent University from October 2010 to December 2020, focusing on immunotherapy approaches for treating solid and haematological cancers through mRNA-nanovaccines, as well as a PhD project researching mRNA-loaded microbubbles for ultrasound-triggered dendritic cell transfection. Heleen holds dual Ph.D. degrees in Pharmaceutical Sciences from Ghent University and Medical Sciences from Vrije Universiteit Brussel, along with a Master’s in Drug Development from Ghent University. Additional experience includes various roles in pharmacy, including an internship and summer positions.
This person is not in any teams
argenx
31 followers
Argenx discovers, designs and develops innovative antibody therapeutics for its own pipeline of treatments for cancer and autoimmune diseases and for its partners. Harnessing our technology and know-how, we aim to meet the needs of patients by engineer...